ABVX Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

101.490

Open

100.550

VWAP

99.49

Vol

1.70M

Mkt Cap

7.91B

Low

97.830

Amount

169.30M

EV/EBITDA(TTM)

Total Shares

79.77M

13.11B

EV/OCF(TTM)

P/S(TTM)

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Events Timeline

(ET)

2026-06-03

12:10:00

Abivax Shares Rise 13.1% to $81.97

2026-06-03

10:10:00

Abivax Stock Rises 14.1% to $82.74

2026-06-02 (ET)

2026-06-02

12:10:00

Abivax Shares Drop 45.0% to $71.38

2026-06-02

10:10:00

Abivax Shares Drop 40.3% to $77.43

News

7.0

06-11PRnewswire

Abivax Under Investigation Following Phase 3 Trial Results, Shares Plummet

7.0

06-10Globenewswire

Abivax Under Investigation for Securities Violations Amid Trial Results

7.0

06-08PRnewswire

Abivax Under Investigation Following Phase 3 Trial Results, Shares Plummet

2.0

06-04NASDAQ.COM

ABIVAX and Others See Significant Stock Gains

9.5

06-03Fool

Abivax's Drug Trial Data Triggers Stock Volatility

8.5

06-03NASDAQ.COM

Abivax's Drug Development Progress and Market Reaction

8 Analyst Rating

Wall Street analysts forecast ABVX stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

131.00

Averages

150.71

High

175.00

Current: 0.000

Low

131.00

Averages

150.71

High

175.00

Wolfe Research

Outperform

NULL

downgrade

$176 -> $136

AI Analysis

2026-06-03

Reason

Wolfe Research

Price Target

$176 -> $136

AI Analysis

2026-06-03

downgrade

Outperform

NULL

Reason

Wolfe Research lowered the firm's price target on Abivax to $136 from $176 and keeps an Outperform rating on the shares. The firm believes the stock is being "over punished" and sees many arguments for why the safety scare should go away upon release of Part 2 data later in June. That said, the prior priced-for-perfection suggests the stock is unlikely to fully recover, Wolfe argues.

Wedbush

Underperform -> Neutral

upgrade

$110 -> $90

2026-06-02

Reason

Wedbush

Price Target

$110 -> $90

2026-06-02

upgrade

Underperform -> Neutral

Reason

As previously reported, Wedbush upgraded Abivax to Neutral from Underperform with a price target of $90, down from $110. The firm notes the company reported placebo-adjusted maintenance clinical remission rates of 40% above its benchmark expectations of 20%-30%, but disclosed malignancies at the higher dose of 50 mg QD. Wedbush views these signals as increasing risk for an eventual black box warning, and prior to approval, an FDA AdComm, especially considering the novel proposed mechanism for obefazimod. Patients may need to remain on a riskier 50 mg dose long-term due to weaker long-term maintenance following de-escalation from 50 mg to 25 mg in a Phase 2 trial, the firm adds. On the positive side, Wedbush recognizes a top-line clinical remission rate of 50% for both 25 and 50 mg cohorts as offering potent monotherapy efficacy.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABVX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Abivax SA (ABVX.O) is 0.00, compared to its 5-year average forward P/E of -9.90. For a more detailed relative valuation and DCF analysis to assess Abivax SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.90

Current PE

0.00

Overvalued PE

0.55

Undervalued PE

-20.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.38

Current EV/EBITDA

-2.10

Overvalued EV/EBITDA

13.77

Undervalued EV/EBITDA

-42.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

280.72

Current PS

87.79

Overvalued PS

965.02

Undervalued PS

-403.57

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks gain $5.00 in 2026

Intellectia · 2622 candidates

Year Price Change Pct: >= $0.01

Ticker

Name

Market Cap$

AXTI

AXT Inc

3.80B

PTN

Palatin Technologies Inc

35.18M

RGC

Regencell Bioscience Holdings Ltd

12.08B

RLMD

Relmada Therapeutics Inc

639.83M

Babcock & Wilcox Enterprises Inc

1.95B

TERN

Terns Pharmaceuticals Inc

5.44B

ابي سهم التارقت حقي يكون اجيب فوق 25% واعلى من راس مالي

Intellectia · 1346 candidates

Year Price Change Pct: >= $25.00

Ticker

Name

Market Cap$

RGC

Regencell Bioscience Holdings Ltd

13.54B

PTN

Palatin Technologies Inc

28.78M

ANPA

Rich Sparkle Holdings Ltd

875.38M

ABVX

Abivax SA

8.86B

SNDK

Sandisk Corp

97.55B

HYMC

Hycroft Mining Holding Corporation

3.20B

what stocks is up more than 500%

Intellectia · 22 candidates

Weekly Average Turnover: >= 1,000,000Year Price Change Pct: >= $500.00

Ticker

Name

Market Cap$

SNDK

Sandisk Corp

73.47B

RGC

Regencell Bioscience Holdings Ltd

10.83B

ABVX

Abivax SA

9.41B

CELC

Celcuity Inc

4.96B

TERN

Terns Pharmaceuticals Inc

3.99B

HYMC

Hycroft Mining Holding Corporation

3.22B

Whales Holding ABVX

Fred Alger Management, LLC

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Point72 Asset Management, L.P.

Boothbay Fund Management, LLC

Nantahala Capital Management, LLC

Deep Track Capital, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Abivax SA (ABVX) stock price today?

The current price of ABVX is 99.15 USD — it has decreased -1

What is Abivax SA (ABVX)'s business?

What is the price predicton of ABVX Stock?

Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is150.71 USD with a low forecast of 131.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Abivax SA (ABVX)'s revenue for the last quarter?

Abivax SA revenue for the last quarter amounts to NaN USD, decreased

What is Abivax SA (ABVX)'s earnings per share (EPS) for the last quarter?

Abivax SA. EPS for the last quarter amounts to USD, decreased

How many employees does Abivax SA (ABVX). have?

Abivax SA (ABVX) has 0 emplpoyees as of June 20 2026.

What is Abivax SA (ABVX) market cap?

Today ABVX has the market capitalization of 7.91B USD.

ABVX Overview

ABVX Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding ABVX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Abivax SA (ABVX) stock price today?

What is Abivax SA (ABVX)'s business?

What is the price predicton of ABVX Stock?

What is Abivax SA (ABVX)'s revenue for the last quarter?

What is Abivax SA (ABVX)'s earnings per share (EPS) for the last quarter?

How many employees does Abivax SA (ABVX). have?

What is Abivax SA (ABVX) market cap?